Watson Barred From Generic Actos Market; Mylan, Teva, Ranbaxy May Enter First
This article was originally published in PharmAsia News
Executive Summary
Watson sues FDA, challenging the agency’s decision not to approve its ANDA for generic Actos while granting market exclusivity to other ANDA filers. The company planned to launch Aug. 17.